Wellfast-SP Tablet is a combination analgesic formulation containing Aceclofenac 100 mg, Paracetamol 325 mg, and Serratiopeptidase 15 mg, designed for the management of pain and inflammation associated with musculoskeletal disorders. Aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), exerts its effect by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis which mediates pain and inflammation. Paracetamol provides analgesic and antipyretic effects through central inhibition of prostaglandin synthesis, complementing the action of Aceclofenac. Serratiopeptidase, a proteolytic enzyme, facilitates the breakdown of inflammatory mediators and promotes the resolution of edema and tissue inflammation. The synergistic combination of these agents offers effective relief from conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and postoperative pain. Wellfast-SP Tablet is indicated for short-term use under medical supervision to minimize potential adverse effects such as gastrointestinal irritation, hepatotoxicity, or hypersensitivity reactions. Caution is advised in patients with a history of peptic ulcers, hepatic or renal impairment, and those on concurrent anticoagulant therapy. Regular monitoring and adherence to prescribed dosage ensure optimal therapeutic outcomes while minimizing risks. Wellfast-SP Tablet should be used as part of a comprehensive pain management plan tailored to individual patient needs.